Repligen Corporation (NASDAQ:RGEN) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 3.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,486 shares of the biotechnology company's stock after buying an additional 16,421 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.84% of Repligen worth $60,843,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of RGEN. Price T Rowe Associates Inc. MD increased its position in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after buying an additional 743,815 shares during the period. Point72 Asset Management L.P. lifted its stake in Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after buying an additional 594,189 shares during the last quarter. Groupama Asset Managment lifted its stake in Repligen by 12,321.0% in the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after buying an additional 400,680 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Repligen in the fourth quarter valued at approximately $53,428,000. Finally, Raymond James Financial Inc. purchased a new stake in Repligen in the fourth quarter valued at approximately $52,492,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Price Performance

NASDAQ:RGEN traded up $0.52 during trading hours on Wednesday, hitting $126.96. The company's stock had a trading volume of 523,165 shares, compared to its average volume of 729,109. The business's 50-day moving average is $127.41 and its two-hundred day moving average is $140.41. The company has a market capitalization of $7.13 billion, a PE ratio of -282.13, a PEG ratio of 3.62 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a 52-week low of $102.97 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. Repligen's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.28 earnings per share. As a group, research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RGEN shares. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Royal Bank Of Canada reduced their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. Finally, Barclays began coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $172.83.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.